Hansoh Pharma (03692.HK) Rises Over 3% on Successful Innovation Transition and Growing Market Share of Third-Generation EGFR-TKI Aumolertinib

According to the Zhicheng Finance APP, Hansoh Pharma (03692) rose over 3%. As of the time of writing, it increased by 2.25%, trading at HK$19.06, with a turnover of HK$67.788 million.

Minsheng Securities released a research report pointing out that Hansoh Pharma's innovation transformation has proven effective. Since the launch of its first self-innovated Class 1.1 new drug, Mailindao, in 2014, the company has had eight innovative drugs approved for marketing. From 2020 to 2023, the revenue share of the company’s innovative drugs rapidly increased, achieving a phased leap from 18% to 42%, then to 53%, and finally to 67%. In the first half of 2024, the combined revenue from innovative drugs and collaborative products reached 5.032 billion yuan, marking an approximately 80.6% increase compared to the same period in 2023, with the share of total revenue rising to 77.40%.

The bank noted that anti-tumor drugs are a traditional strength of the company. In 2023, the company's anti-tumor drug revenue reached 6.169 billion yuan, accounting for 59.7%. In the first half of 2024, the company's anti-tumor drug revenue reached 4.475 billion yuan, accounting for 68.8%. Currently, the company has formed a healthy product portfolio and a rich R&D pipeline in the anti-tumor field: the market share of the third-generation EGFR TKI Aumolertinib continues to rise, contributing significantly to revenue growth; the second-generation Bcr-Abl TKI Flumatinib shows better efficacy than Imatinib, with a clear trend of substitution; the subsequent oncology R&D pipeline is robust, covering multiple promising targets, especially the two ADC products licensed to GSK, which are expected to bring continuous licensing income to the company. The bank is optimistic about the company’s continued efforts in the oncology field, maintaining and strengthening its leading position in this area.